Immuto Scientific is developing a platform that integrates artificial intelligence with mass spectrometry to accelerate protein structure determination. The company, co-founded in 2018 by CEO Faraz A. Choudhury and CTO Daniel Benjamin, focuses on streamlining workflows for analyzing antibody-antigen complexes. Its approach is designed to address significant bottlenecks in traditional cryo-electron microscopy methods.
Cryo-EM can deliver high-resolution protein structures, but sample preparation and grid optimization remain major hurdles. Immuto's technology targets these specific challenges, aiming to increase throughput for selected applications. The firm's founders, both electrical engineers by training, are applying their expertise to this biophysical problem.
The company's narrower pitch centers on improving workflows for antibody-antigen analysis, a critical area in drug discovery and biologics development. By pairing AI with mass spectrometry, the startup seeks to provide a more efficient path to structural insights. This could potentially speed up the characterization of therapeutic candidates.
If successful, Immuto's platform could impact the early stages of biopharmaceutical research, where understanding protein interactions is fundamental. The technology aims to reduce the time and resource intensity currently associated with obtaining structural data. This efficiency gain would be particularly valuable for companies developing antibody-based therapies.